Dogwood Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
1.380
+0.010 (0.73%)
At close: Jul 17, 2026, 4:00 PM EDT
1.389
+0.009 (0.67%)
After-hours: Jul 17, 2026, 7:27 PM EDT
Dogwood Therapeutics Employees
Dogwood Therapeutics had 8 employees as of December 31, 2025. The number of employees decreased by 4 or -33.33% compared to the previous year.
Employees
8
Change (1Y)
-4
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$3,539,879
Market Cap
46.41M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | -4 | -33.33% |
| Dec 31, 2024 | 12 | 8 | 200.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | -1 | -20.00% |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 118 |
| aTyr Pharma | 60 |
| Mereo BioPharma Group | 39 |
| eXoZymes | 32 |
| INmune Bio | 21 |
| Filana Therapeutics | 20 |
| Instil Bio | 17 |
| Eloxx Pharmaceuticals | 10 |
DWTX News
- 19 days ago - Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board - GlobeNewsWire
- 19 days ago - Dogwood Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - Dogwood begins Phase 2b extension study for Halneuron - TheFly
- 2 months ago - Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study - GlobeNewsWire
- 2 months ago - Dogwood Therapeutics Earnings release: Q1 2026 - Filings
- 2 months ago - Dogwood Therapeutics Quarterly report: Q1 2026 - Filings
- 2 months ago - Dogwood Therapeutics Announces First Quarter 2026 Financial Results - GlobeNewsWire
- 2 months ago - Dogwood Therapeutics Slides: Corporate presentation - Filings